CYP2C19 Poor Metabolizer Is Associated With Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction But Not Stable Angina

BACKGROUND—More intensive platelet suppression is required in patients with acute myocardial infarction (AMI) than in those with stable angina because of differential platelet activation between AMI and stable angina. In this context, CYP2C19 genotype leading to reduced active metabolite formation m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation. Cardiovascular genetics 2013-10, Vol.6 (5), p.514-521
Hauptverfasser:	Kim, Ho-Sook, Chang, Kiyuk, Koh, Yoon-Seok, Park, Mahn-Won, Choi, Yun-Seok, Park, Chul-Soo, Oh, Minkyung, Kim, Eun-Young, Shon, Ji-Hong, Shin, Jae-Gook, Seung, Ki-Bae
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Alleles Angina, Stable - drug therapy Angina, Stable - genetics Angina, Stable - mortality Aryl Hydrocarbon Hydroxylases - genetics Aryl Hydrocarbon Hydroxylases - metabolism Cytochrome P-450 CYP2C19 Female Genotype Humans Kaplan-Meier Estimate Male Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - mortality Platelet Aggregation Inhibitors - therapeutic use Proportional Hazards Models Risk Factors Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!